ORKA Stock: Price, Earnings History and SEC Filings
Oruka Therapeutics, Inc. (ORKA) last traded at $96.87, up 0.23% on the latest session and up 16.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.55 against an analyst estimate of $-0.49, a miss of 12.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ORKA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.55 | $-0.49 | -12.24% |
| Mar 2026 | May 13, 2026 | $-0.48 | $-0.52 | +7.69% |
| Dec 2025 | Mar 12, 2026 | $-0.45 | $-0.61 | +26.23% |
| Sep 2025 | Nov 12, 2025 | $-0.55 | $-0.56 | +1.79% |
ORKA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How ORKA reacts to earnings
Across its last 6 earnings releases, ORKA moved 4.7% on average the next session, in either direction. It rose after 5 of 6 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | Before open | +6.40% |
| 2026-04-30 | After close | -8.52% |
| 2024-09-05 | After close | +2.80% |
| 2024-08-01 | After close | +5.07% |
| 2024-04-25 | After close | +2.87% |
| 2024-02-01 | After close | +2.53% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ORKA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2023 | $0 | -$5M | -$5M | – | $-0.37 |
| 2022 | $0 | -$10M | -$11M | – | $-0.69 |
| 2021 | $0 | -$19M | -$19M | – | $-1.39 |
| 2020 | $0 | -$10M | -$8M | – | – |
| 2019 | $0 | -$5M | -$5M | – | – |
| 2018 | $0 | -$8M | -$8M | – | – |
| 2017 | $0 | -$18M | -$17M | – | – |
| 2016 | $0 | -$16M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ORKA
- 8-K · Oct 26, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 424B5 · Aug 28, 2026
- 8-K · Aug 24, 2026Officer or director change, Financial statements and exhibits
- S-3 · Aug 21, 2026
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote
- 8-K · Jun 1, 2026Other events, Financial statements and exhibits
- 10-Q · May 13, 2026
- 8-K · Apr 30, 2026Results of operations, Other events, Financial statements and exhibits
Insider filing activity
ORKA insiders filed 17 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ORKA news
- Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial ResultsOct 27, 2026 · finance.yahoo.com
- Oruka Therapeutics Reports Strong Phase 2b Psoriasis ResultsOct 27, 2026 · theglobeandmail.com
- Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis StudyOct 27, 2026 · marketbeat.com
- Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift”Oct 26, 2026 · tikr.com
- Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 MonthsOct 26, 2026 · stocktwits.com
- Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe PsoriasisOct 26, 2026 · finance.yahoo.com
- Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech WatchlistOct 26, 2026 · stocktwits.com
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026Oct 25, 2026 · finance.yahoo.com
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. (ORKA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.